Cell & Gene, the most valuable online resource for delivering in-depth content from authoritative authors and sources to professionals in the CGT sector, introduces Cell & Gene: The Podcast. In each episode, Cell & Gene Chief Editor, Erin Harris, will talk to industry and academic leaders about their current initiatives and how they are moving the sector forward.
Understanding CAR-M Technology with Carisma Therapeutics' Dr. Debora Barton
Carisma Therapeutics’ Dr. Barton breaks down the latest in CAR-M technology as well as the company's Phase 1 First-in-Human Study of Adenovirally Transduced Anti-HER2 CAR Macrophages in Subjects with HER2 Overexpressing Solid Tumors.
Inside the Gene Therapy for Coronary Artery Disease with XyloCor Therapeutics' Albert Gianchetti
XyloCor Therapeutics' EXACT clinical trial is a Phase 1/2 multicenter, open-label, single arm, dose escalation trial for coronary artery disease — the most common type of heart disease — with gene therapy at its center.
Advancing Patient Engagement with Novartis Gene Therapies' Dr. Amy Nicole Nayar
Dr. Amy Nicole Nayar, VP of US Patient Advocacy and Government Affairs at Novartis Gene Therapies explains what patient engagement should encompass in the cell and gene field as well as the unique challenges cell and gene therapy companies face where a patient engagement officer provides essential help.
BridgeBio's Approach to Gene Therapy & Nearing the Clinic
BridgeBio's CEO of Gene Therapy, Dr. Eric David, explains the company's gene therapy programs for Canavan disease and congenital adrenal hyperplasia, their manufacturing plans, and the platform underpinning their novel approach to gene therapy.
Inside Spark Therapeutics' Investigational SPK-8011 for Hemophilia A
Spark Therapeutics' Clinical Development Lead, Hematology, Dr. Tiffany Chang explains the company's data from its ongoing Phase 1/2 clinical trial of investigational SPK-8011 for hemophilia A, the largest gene therapy trial in this disease to date as well as the misconceptions and unknowns about the disease.
Gene Therapies for Spinal Cord-Related Disorders with SwanBio's CEO
Karen Kozarsky, Ph.D., Co-Founder and CSO of SwanBio, explains how the company is pioneering a deep and varied pipeline of gene therapies for genetically defined neurological diseases with a focus on the spinal cord.